Search the Community
Showing results for tags 'study'.
Found 5 results
-
This organization is looking for people who are willing to share their opinions about Non-Small Cell Lung Cancer. They are looking to speak with patients (ages 18-80) and caregivers with Stage III or IV Non-Small Cell Lung Cancer. Qualified participants will be compensated $100 (Telephone Interview) OR $150 (Focus Group) for their time and opinion. Anyone who is interested can email Patient.Research@schlesingerassociates.com to see if they are a good fit for the interviews! Please see the attached flyer for complete information. Non Small Cell Lung Cancer _ Flyer.pdf
-
Trialbee is recruiting for a clinical study to evaluate an investigative treatment for Lung Neuroendocrine Tumors (Lung NETs). You may have heard of this condition being called Lung Carcinoid Tumors, Bronchial NETs, or Pulmonary NETs. A total of 216 patients will be a part of this global study, which has been approved by the FDA and relevant ethics committees. We are looking for both males and females, aged 18 years or older, who are diagnosed with a neuroendocrine tumor of the lung (Lung NET). To find out if the study may be suitable for you, please visit this website. This post has been approved by LUNGevity Foundation.
-
LUNGevity Foundation has launched Patient FoRCe, the first-ever critical bridge to connect the voices of lung cancer patients — a significant population — with health care professionals, regulators, policymakers, and developers of drugs. “Lung cancer is the #1 cancer killer, taking the lives of 157,000 Americans every year. LUNGevity is leading the way in changing the paradigm of cancer treatment ─ from assuming patient wishes to evidence-based conclusions about what patients value,” said LUNGevity Chairman Andrea Stern Ferris. “Through Patient FoRCe, lung cancer patient voices will be heard and heeded as policy is developed, research is conducted, and treatment decisions are made.” Patient FoRCe, LUNGevity’s Patient-Focused Research Center, will undertake never-before studies of those living with lung cancer, collecting and sharing robust qualitative and quantitative data about lung cancer patients’ preferences and experiences to inform treatment, as well as relevant policy and research protocols. Patient FoRCe’s immediate focus will include continuing a study of patient preferences and experiences regarding access to care, treatment and diagnostic options, and the impact of symptoms on daily living, as well as conducting studies to facilitate patients’ access to biomarker testing, which is essential to implementing precision medicine. Patient FoRCe will also initiate a study into increasing adherence to lung cancer screening protocols for people at high risk for lung cancer. Additional projects will be based on stakeholder input and the guidance of an external advisory board of survivors, academic and community clinicians, industry partners, patient advocacy groups, and community partners. LUNGevity formally announced Patient FoRCe at the American Association for Cancer Research’s 2017 Annual Meeting in Washington, DC, on Sunday, April 2. Andrea Stern Ferris spoke to the urgency of the initiative, saying, “For too long, public policy, the practice of medicine, and drug development have not adequately integrated the viewpoint of patients. LUNGevity is determined to change that paradigm. By incorporating the patient’s voice into every step of the process – in policymaking, in trials, in treatments – we will improve outcomes for those diagnosed with lung cancer.” “Our goal is to uncover gaps in information, misperceptions about patient attitudes, and areas of unmet patient need,” explained Dr. Upal Basu Roy, Director of Patient FoRCe. “LUNGevity is the only organization driving this type of change for the lung cancer community, and we anticipate that our findings will shape the future of lung cancer care.” For more information about Patient FoRCe, visit www.LUNGevity.org/patientforce. Click here to read the full press release. -
A market research company has asked us to share a survey opportunity for patients within the US with Stage IV lung cancer. Those who qualify and complete the 60-minute telephone survey will be compensated if you complete the screener and telephone interview. To see if you qualify for this survey, click here www.alphadetail.com/lcpatientstudy Please note: you will only be compensated for completing this in its entirety once. If you need any additional information please contact Elizabeth Lawson (ELawson@us.imshealth.com)
-
Study Announcement: Lung Cancer Caregiver Study If you are over the age of 18 and a romantic partner and the caregiver of someone who has been diagnosed with lung cancer in the past two years, please consider contributing to this important study on the quality of life of caregivers of lung cancer patients and survivors. This study consists of completing a brief online survey at 2 different time points over the course of six months (initial time point and 6 months later). Some find the surveys helpful for reflecting on their caregiving experience, and you would be contributing to our understanding of the important but understudied topic of the challenges faced by caregivers. The survey questions will ask you about your feelings about caregiving, your quality of life, your physical health, and the physical health of the lung cancer survivor for whom you are a caregiver. The survey will take approximately 30 minutes at each of the two time points. This research is being conducted by Trisha Raque-Bogdan, Ph.D. of the University of Denver and Amanda Ginter, Ph.D., of Towson University. If you would like to participate in this research, please either go to https://udenver.qualtrics.com/SE/?SID=SV_etkPpCNDT9HwkKN or contact Trisha Raque-Bogdan at trisha.raque-bogdan@du.edu. Thank you for your consideration! Trisha Raque-Bogdan, Ph.D. Assistant Professor, Counseling Psychology University of Denver Amanda Ginter, Ph.D. Assistant Professor, Family Studies Towson University This study has been approved for posting by LUNGevity Foundation.
